Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meropenem/vaborbactam - Melinta Therapeutics

Drug Profile

Meropenem/vaborbactam - Melinta Therapeutics

Alternative Names: Carbavance™; Meropenem and vaborbactam; Meropenem trihydrate/vaborbactam; Meropenem/RPX-7009; RPX-2014/RPX-7009; RPX-7009/RPX-2014; Vabomere

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rempex Pharmaceuticals
  • Developer Melinta Therapeutics; Rempex Pharmaceuticals; US Department of Health and Human Services
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Urinary tract infections
  • Registered Bacteraemia; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pyelonephritis
  • Phase III Pneumonia

Most Recent Events

  • 28 Aug 2019 No recent reports of development identified for phase-I development in Gram-negative-infections(In adolescents, In children, In infants) in USA (IV, Infusion)
  • 13 Mar 2019 Meropenem/vaborbactam - Melinta Therapeutics is available for licensing in Latin America as of 13 Mar 2019. https://melinta.com/
  • 09 Jan 2019 Melinta Therapeutics withdraws the phase III TANGO 3 trial in Nosocomial pneumonia in USA and European Union, prior to enrolment (NCT03006679)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top